Efficient transduction and seeding of human endothelial cells onto metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor

Koren, Belly; Weisz, Anat; Fischer, Lukáš; Gluzman, Zoya; Preis, Meir; Avramovitch, Naomi A.; Cohen, Tzafra; Cosset, François‐Loïc; Lewis, Basil S.; Flugelman, Moshe Y.

doi:10.1016/j.carrev.2005.12.007

Cited by 25 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we showed that the CFS FRA11H is a preferential site for MLV-based vectors. Many fragile sites are involved in genomic instability in cancer43. It is important to note that 11q13, the chromosomal band harboring FRA11H, is a known hotspot for genomic instability in different types of cancer (Supplementary Table 1), although further studies are required to shed light on the importance of FRA11H sequences as a hotspot for genomic instability in cancer.…”

Section: Discussionmentioning

confidence: 99%

Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites

Bester

Kafri

Maoz

et al. 2013

Sci Rep

View full text Add to dashboard Cite

Genome instability is a hallmark of cancer. Common fragile sites (CFSs) are specific regions in the human genome that are sensitive to replication stress and are prone to genomic instability in different cancer types. Here we molecularly cloned a new CFS, FRA11H, in 11q13. The genomic region of FRA11H harbors a hotspot of chromosomal breakpoints found in different types of cancer, indicating that this region is unstable during cancer development. We further found that FRA11H is a hotspot for integrations of Murine Leukemia Virus (MLV)-based vectors, following CD34+ infections in vitro as well as ex-vivo during gene therapy trials. Importantly, we found that the MLV-based vector infection in-vitro leads to replication perturbation, DNA damage and increased CFS expression. This suggests that infection by MLV-based vectors leads to replication-induced genome instability, raising further concerns regarding the use of retroviral vectors in gene therapy trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites

Bester

Kafri

Maoz

et al. 2013

Sci Rep

View full text Add to dashboard Cite

show abstract

“…[Flugelman et al, 1992b;Preis M et al, 2006] Retroviral vectors can accommodate 6 to 7 kb of transgenes. Pseudotyping of the vector envelope can improve gene transfer efficiency to vascular cells [Cosset et al, 1995;Koren et al, 2006]. Use of current retroviral vectors is limited for cardiovascular application however use for ex vivo gene transfer is being tested in several phase I studies.…”

Section: Vectors For Gene Deliverymentioning

confidence: 99%

Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient

Staudacher

Flugelman²

2006

CGT

View full text Add to dashboard Cite

Morbidity and mortality attributed to diseases of the heart and blood vessels are growing steadily around the globe, as a result of changing lifestyles and increased longevity. Even in affluent countries many patients with cardiovascular syndromes do not benefit from current conventional therapies. Failure of drugs, catheter-based, and surgical interventions leaves millions of patients in a great need for new therapies. Cell and gene therapy hold great promise for cardiovascular therapies. As most cardiovascular pathologies are confined to a specific organ and are associated with arterial occlusion or muscle damage, both may be amenable to local cell and gene therapies. Local delivery of genes or cells that can promote the formation of new blood vessels (angiogenesis) or lead to tissue regeneration should be achievable with current knowledge and molecular technologies. So far, however, the promise of gene and cell therapy has not fulfilled the expectations. Nevertheless, careful review of the work and of current thinking in the field leaves room for optimism that gene and cell therapy may reach the clinical setting in the near future, providing a new option for many patients. In this paper, we review clinical studies of gene and cell therapy and discuss their impact on future research.

show abstract

“…Human primary venous ECs and SMCs at passage 2 (p2) [11] were cultured at 37°C in a 5% CO 2 environment. ECs were cultured in MCDB 131 (Gibco, USA) supplemented with 10 mM GlutaMax (Gibco, USA), 20% FBS (Hyclone, USA), 5 U ml À1 heparin (American Pharmaceutical, USA), 100 U ml À1 penicillin, 0.1 mg ml À1 streptomycin, 0.25 lg ml À1 Amphotericin B and 6 ll ml À1 of basic fibroblast growth factor (bFGF, Biological Industries, Israel).…”

Section: Cell Lines and Culturementioning

confidence: 99%

“…Although the use of bare endoluminal metallic stents has significantly lowered this rate [4][5][6][7], in-stent restenosis (ISR), associated with intimal hyperplasia [2] still remains a major limitation [2]. Drug-eluting stents (DES) reduce the occurrence of ISR [8][9][10] and associated neointimal formation [11,12]; however, their limited ability to control drug dosage, as well as inflammatory side effects elicited by the polymer coatings, result in slower and incomplete healing [13]. There are also complications regarding the long-term implications of late stent thrombosis [9,14].…”

Section: Introductionmentioning

confidence: 99%

The formation of an anti-restenotic/anti-thrombotic surface by immobilization of nitric oxide synthase on a metallic carrier

et al. 2014

View full text Add to dashboard Cite

Efficient transduction and seeding of human endothelial cells onto metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor

Cited by 25 publications

References 20 publications

Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites

Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites

Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient

The formation of an anti-restenotic/anti-thrombotic surface by immobilization of nitric oxide synthase on a metallic carrier

Contact Info

Product

Resources

About